VIDEO: IU among the founding members of Indiana IoT Lab-Fishers

Bill Stephan, IU Vice President for Engagement
Bill Stephan, IU Vice President for Engagement

Indiana University Vice President for Engagement Bill Stephan was among state, local and industry leaders who announced plans to create a 25,000-foot facility in Fishers.

Indiana IoT Lab-Fishers is located in the city’s Certified Tech Park. The goal is to encourage collaboration and innovation within the Internet of Things industry. Member companies will be allowed to set up temporary or permanent residence, while non-members can bring IoT-related questions to the space for others to answer.

A video of Stephan speaking at the Indiana IoT Lab-Fishers announcement is available here.

Additional video of the announcement is available here.

FDA approves Phase 1 study of Apexian Pharmaceuticals’ lead compound

Congratulations to Apexian Pharmaceuticals!

The U.S. Food & Drug Administration has authorized the clinical stage biotechnology company to begin the Phase 1 study of APX3330, its lead compound.

headshot of Steve Carchedi
Steve Carchedi, President and CEO, Apexian Pharmaceuticals

Steve Carchedi, President and Chief Executive Officer of Apexian Pharmaceuticals, said, “We are very excited to have reached this important milestone in the evaluation of APX3330 in patients with cancer and will begin study accrual in the coming months.”

Apexian Pharmaceuticals licenses technology from the Indiana University Research and Technology Corp. A news release about the FDA’s approval to begin the Phase 1 study is available here.

IUPUI students to showcase their entrepreneurial talents during the 2017 JagStart competition!

Major League Baseball may be in the midst of spring training, but very important pitches will happen Friday, March 3 in Indianapolis

Fifteen teams of Indiana University-Purdue University Indianapolis students will compete for $5,500 during the 2017 JagStart competition, 1:30-3:30 p.m. in the Lilly Auditorium of the IUPUI library.

The teams have three minutes to share product or venture ideas, and answer questions from a five-judge panel for two minutes.

Preview the 2017 competition here. Read about the 2016 competition here.

Good luck to these entrepreneurs on Friday!

Inside Indiana Business reports on healthcare software startup Digital Health Solutions

headshot of Dr. Stephen Downs
Dr. Stephen Downs, President, Digital Health Solutions LLC

Digital Health Solutions is a software startup founded by Dr. Stephen Downs and Tammy Dugan, two members of the Indiana University School of Medicine.

The company’s first product, software called CHICA, or Child Health Improvement through Computer Automation, has been used at Eskenazi Hospital for several years. The company licenses the technology through Indiana University Research and Technology Corp. and is a member of the Spin Up entrepreneurial program.

Inside Indiana Business reports on the company in an article that you can read here. There are two audio files attached to the article.

Tammy Dugan, chief technology officer, Digital Health Solutions LLC
Tammy Dugan, chief technology officer, Digital Health Solutions LLC

A news release about the company is available here.

Congratulations to Dr. Downs and Dugan on launching Digital Health Solutions!

Watch Jennifer Finefield of IURTC on Inside Indiana Business with Gerry Dick!

headshot of Jennifer Finefield
Jennifer Finefield, Senior Technology Manager, Indiana University Research and Technology Corporation

Jennifer Finefield, senior technology manager at Indiana University Research and Technology Corp., appeared on Inside Indiana Business with Gerry Dick to speak about a record year in prototype development for a collaboration between IURTC and Rose-Hulman Ventures.

You can watch the five-minute interview here.

A news release about the collaboration is available here.

Well done, Jennifer!

Jennifer Finefield of IURTC to appear on Inside Indiana Business TV!

Jennifer Finefield (IURTC) and Elizabeth Hagerman (Rose-Hulman Ventures) sit on one side of a curved desk branded "Inside Indiana Business" across from Gerry Dick, the show's host.
Jennifer Finefield (L) of IURTC and Elizabeth Hagerman of Rose-Hulman Ventures speak with Gerry Dick of “Inside Indiana Business with Gerry Dick” about the collaboration between the organizations.

Jennifer Finefield, senior technology manager at Indiana University Research and Technology Corp., will appear on “Inside Indiana Business with Gerry Dick” alongside Elizabeth Hagerman of Rose-Hulman Ventures.

They will speak with Gerry Dick about the collaboration between the two organizations, which culminated in a record eight prototypes being developed in the 2016 calendar year.

WFYI, the PBS station in Indianapolis, will broadcast the interview Friday, February 24 at 7:30 p.m. WTIU, the PBS station in Bloomington, will broadcast it Saturday, February 25 at 4:30 p.m. The complete listing of “Inside Indiana Business with Gerry Dick” broadcast days and times is available here.

A news release about the record year for the IURTC/Rose-Hulman Ventures collaboration is available here.

Well done, Jennifer!

Drone tech company that received Innovate Indiana Fund investment announces partnership

PrecisionHawk, which received an investment from the Innovate Indiana Fund, has more great news!

The company has selected Sierra Wireless AirPrime® MC Series embedded modules to enable global LTE connectivity for its Low Altitude Traffic and Airspace Safety (LATAS) platform, which enables safe drone operation on a broad scale.

Congratulations to PrecisionHawk! You can read a news release here.

CEO of company that licenses IU cancer pharmaceutical research scheduled to speak in Philadelphia

Steve Carchedi, President and CEO of Apexian Pharmaceuticals, is scheduled to speak March 1 at Drexel University’s Healthcare Guest Lecture Series in Philadelphia.

headshot of Steve Carchedi
Steve Carchedi, President and CEO, Apexian Pharmaceuticals

“Drexel has a wonderful history of developing leaders in the healthcare industry,” Carchedi said. “We are honored to partner with faculty at Drexel to attract talent to pursue development of life-saving medicines, like our lead molecule, APX3330, that is ready to advance into the clinic. Hopefully, some of these students will be leading the effort for future breakthrough medicines.”

Apexian Pharmaceuticals, formerly ApeX Therapeutics, recently announced acceptance by the U.S. Food and Drug Administration of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330, a small molecule in development to treat late stage cancer. The company licenses IU-discovered research through Indiana University Research and Technology Corp.

A news release about Carchedi and Drexel University’s Healthcare Guest Lecture Series is available here.